InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,626.02
(
0.00%
)
US TECH 100
18,936.40
(
-0.41%
)
Dow Jones
41,393.78
(
0.00%
)
Brent Oil
71.97
(
0.81%
)
Bitcoin
58,615.26
(
-0.95%
)
Post# of 253125
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120436
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: pcrutch post# 114845

Friday, 01/13/2012 7:21:04 AM

Friday, January 13, 2012 7:21:04 AM

Post# of 253125
Barron’s compliments itself on its great MNTA call from Feb 2011 (LOL):

http://online.barrons.com/article/SB50001424052748704284404577157213125724728.html

Generic-drug maker Momenta Pharmaceuticals (MNTA) jumped more than 31% after we published our story in February, compared to a 9% decline by the relevant benchmark.

In truth, Barron’s Feb 2011 article on MNTA was moronic (as noted in #msg-59968048).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up